Skip to main content
. 2016 Jan 8;7(5):6088–6104. doi: 10.18632/oncotarget.6842

Figure 8. Cdk5 inhibition sensitizes to anti-angiogenic treatment.

Figure 8

LLC tumors from control (co) or Cdk5fl/flVECCre mice treated with solvent or the anti-VEGF antibody B20–4.1.1 are shown. Quantification of tumor weight is indicated. ANOVA on Ranks, Dunn's Method, SEM, *p ≤ 0.05. control/solvent n = 10, control/anti-VEGF n = 9, Cdk5fl/flVECCre/solvent n = 9, Cdk5fl/flVECCre/anti-VEGF n = 8.